Celgene Co. (CELG) Position Cut by Pillar Pacific Capital Management LLC

Pillar Pacific Capital Management LLC lessened its stake in Celgene Co. (NASDAQ:CELG) by 1.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 80,694 shares of the biopharmaceutical company’s stock after selling 1,090 shares during the period. Pillar Pacific Capital Management LLC’s holdings in Celgene were worth $7,612,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CELG. Altium Wealth Management LLC lifted its holdings in Celgene by 1.3% in the 1st quarter. Altium Wealth Management LLC now owns 8,980 shares of the biopharmaceutical company’s stock valued at $847,000 after acquiring an additional 115 shares during the last quarter. Janney Capital Management LLC lifted its holdings in Celgene by 2.9% in the 4th quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 120 shares during the last quarter. Community Bank N.A. lifted its holdings in Celgene by 3.2% in the 1st quarter. Community Bank N.A. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 120 shares during the last quarter. Iberiabank Corp lifted its holdings in Celgene by 1.0% in the 1st quarter. Iberiabank Corp now owns 12,019 shares of the biopharmaceutical company’s stock valued at $1,134,000 after acquiring an additional 121 shares during the last quarter. Finally, Pitcairn Co. lifted its holdings in Celgene by 3.0% in the 4th quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 124 shares during the last quarter. Hedge funds and other institutional investors own 71.71% of the company’s stock.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Mizuho set a $103.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Friday, April 5th. Barclays downgraded shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target for the company. in a report on Friday, May 3rd. Finally, BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a research note on Thursday, April 25th. Twenty analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Celgene currently has an average rating of “Hold” and a consensus target price of $95.96.



CELG stock opened at $94.15 on Wednesday. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42. Celgene Co. has a one year low of $58.59 and a one year high of $97.07. The stock has a market cap of $66.33 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 0.43 and a beta of 1.68.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.01 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. The business’s quarterly revenue was up 13.8% on a year-over-year basis. Sell-side analysts predict that Celgene Co. will post 9.85 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Celgene Co. (CELG) Position Cut by Pillar Pacific Capital Management LLC” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://dakotafinancialnews.com/2019/05/15/celgene-co-celg-position-cut-by-pillar-pacific-capital-management-llc.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.